NEA Management Company, LLC
An institutional investment manager in TIMONIUM, MD. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1512848.
- Reported value$1.59bn
- Positions26
Holdings: 26 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Trevi Therapeutics, Inc.TRVI | COM | 89532M101 | 247 | 15.5% | 13,222,228 | Unchanged | |
| MBX Biosciences, Inc.MBX | COM | 55287L101 | 200 | 12.6% | 3,614,486 | Unchanged | |
| Monte Rosa Therapeutics, Inc.GLUE | COM | 61225M102 | 186 | 11.7% | 7,692,298 | Unchanged | |
| Celcuity Inc.CELC | COM | 15102K100 | 179 | 11.3% | 1,710,561 | Reduced−575,000 | |
| Spyglass Pharma, Inc.SGP | COM SHS | 85220G109 | 165 | 10.4% | 7,392,301 | Unchanged | |
| Savara, Inc.SVRA | COM | 805111101 | 151 | 9.5% | 24,471,264 | Unchanged | |
| Zenas BioPharma, Inc.ZBIO | COM | 98937L105 | 102 | 6.4% | 4,023,219 | Unchanged | |
| Coursera, Inc.COUR | COM | 22266M104 | 72.6 | 4.6% | 12,867,769 | Unchanged | |
| Aurinia Pharmaceuticals, Inc.AUPH | COM | 05156V102 | 67.4 | 4.2% | 3,969,834 | Unchanged | |
| CRISPR Therapeutics AG | NAMEN AKT | H17182108 | 57.7 | 3.6% | 1,058,570 | Unchanged | |
| ORIC Pharmaceuticals, Inc.ORIC | COM | 68622P109 | 44.6 | 2.8% | 4,118,621 | Unchanged | |
| Phathom Pharmaceuticals, Inc.PHAT | COM | 71722W107 | 21.3 | 1.3% | 1,960,169 | Unchanged | |
| Korro Bio, Inc.KRRO | COM | 500946108 | 17.1 | 1.1% | 1,297,893 | Unchanged | |
| X4 Pharmaceuticals, Inc. | COM | 98420X103 | 15.1 | 1.0% | 3,233,743 | Unchanged | |
| Champions Oncology, Inc.CSBR | COM NEW | 15870P307 | 10.6 | 0.7% | 1,713,720 | Unchanged | |
| Nkarta, Inc.NKTX | COM | 65487U108 | 10.1 | 0.6% | 3,568,781 | Unchanged | |
| CVRx, Inc.CVRX | COM | 126638105 | 10.0 | 0.6% | 1,954,440 | Reduced−71,643 | |
| Black Diamond Therapeutics, Inc.BDTX | COM | 09203E105 | 8.2 | 0.5% | 4,448,757 | Unchanged | |
| Karyopharm Therapeutics Inc.KPTI | COM NEW | 48576U205 | 5.6 | 0.4% | 576,780 | New+576,780 | |
| Inventiva SAIVA | ADS | 46124U107 | 5.5 | 0.3% | 1,462,586 | Unchanged | |
| LeonaBio, Inc.LONA | COM | 04746L203 | 4.3 | 0.3% | 464,398 | Unchanged | |
| Senti Biosciences, Inc. | COM NEW | 81726A209 | 4.2 | 0.3% | 3,775,615 | Unchanged | |
| Marker Therapeutics, Inc.MRKR | COM NEW | 57055L206 | 2.4 | 0.2% | 1,625,678 | Unchanged | |
| OnKure Therapeutics, Inc.OKUR | COM CL A | 68277Q105 | 2.2 | 0.1% | 478,548 | Unchanged | |
| ImageneBio, Inc.IMA | COM | 45175G207 | 0.3 | <0.1% | 50,005 | Unchanged | |
| Gossamer Bio, Inc. | COM | 38341P102 | 0.2 | <0.1% | 1,000,000 | Unchanged |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Arcellx, Inc. | COMMON STOCK | 03940C100 | 0.0 | 0.0% | 0 | Sold out−3,045,262 |
Source: SEC EDGAR, Form 13F-HR, accession 0001072613-26-000684 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.